Home / Stocks / Ajanta Pharma Limited
AJANTPHARM

Ajanta Pharma Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹3,270.3

Change

-3.5 (-0.11%)

Open

₹3,282.6

Prev. Close

₹3,273.8

Day High

₹3,303.1

Day Low

₹3,243.4

Volume Analysis

Traded

128,803

Delivered

91,738

Delivery %

71.22%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (27.1%)
  • •Strong operating margin (27.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (1)

  • •Strong 3-year EPS growth (22.6%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹3,360.84 ₹3,331.97 ₹3,301.14 ₹3,272.27 ₹3,241.44 ₹3,212.57 ₹3,181.74
Fibonacci ₹3,331.97 ₹3,309.16 ₹3,295.08 ₹3,272.27 ₹3,249.46 ₹3,235.38 ₹3,212.57
Camarilla ₹3,286.72 ₹3,281.25 ₹3,275.77 ₹3,272.27 ₹3,264.83 ₹3,259.36 ₹3,253.88

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+11.3%

1 Week

-1.62%

1 Month

+0.31%

3 Months

-10.15%

6 Months

+5.24%

1 Year

+30.25%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹860.09

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

22.8%

Net margin 20.32% × asset turnover 0.85x × equity multiplier 1.32x

Company Overview

Sector

Healthcare

Market Cap

₹41,393 Cr

P/E (TTM)

32.8

ROE

27.1%

Book Value

₹389.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Ajanta Pharma Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Valuation (19/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (27.1%); strong operating margin (27.0%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

70/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

72

Valuation

19

Cash Flow

25

Corporate Governance

76

Momentum

64

Institutional Ownership

52

Business Quality

100

Risk & Volatility

84

Liquidity

86

From Screener.in

  • +Company is almost debt free.
  • +Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%
  • +Company has been maintaining a healthy dividend payout of 50.1%
  • −Stock is trading at 8.52 times its book value

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Ajanta Pharma files revised SAST pledge disclosures for Aayush Agrawal Trust, correcting lender details for 30,000 and 4,60,000 shares.

Pls find enclosed newspaper publication of financial results for the quarter ended 30.09.2026.

Q2FY2027 earnings call audio recording uploaded on 30 October 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 1,028 1,105 1,054 1,145 1,187 1,146 1,170 1,303 1,354 1,375 1,422 1,626 1,794
Expenses + 738 791 776 815 875 825 873 951 1,026 993 1,088 1,202 1,247
Operating Profit 291 314 278 330 311 321 297 351 328 382 333 424 548
OPM % 28.0% 28.0% 26.0% 29.0% 26.0% 28.0% 25.0% 27.0% 24.0% 28.0% 23.0% 26.0% 31.0%
Other Income + 21 14 36 26 19 30 18 26 59 25 61 71 37
Interest 2 2 2 1 6 8 6 5 3 5 2 3 2
Depreciation 34 34 34 34 34 36 40 41 43 44 45 44 48
Profit before tax 276 291 278 322 290 307 269 331 341 359 347 447 535
Tax % 29.0% 28.0% 27.0% 24.0% 25.0% 24.0% 16.0% 23.0% 24.0% 24.0% 23.0% 25.0% 27.0%
Net Profit + 195 210 203 246 216 233 225 255 260 274 267 334 388
EPS in Rs 15 16 16 20 17 19 18 20 21 22 21 27 31
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 10 14 20 12 15 4 11 14 14 20 21 25 33

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 1,474 1,749 1,983 2,126 2,055 2,588 2,890 3,341 3,743 4,209 4,648 5,453 6,217
Expenses + 968 1,155 1,292 1,467 1,489 1,904 1,889 2,408 2,934 3,037 3,379 3,953 4,530
Operating Profit 505 594 691 658 567 683 1,001 933 808 1,172 1,269 1,500 1,687
OPM % 34.0% 34.0% 35.0% 31.0% 28.0% 26.0% 35.0% 28.0% 22.0% 28.0% 27.0% 28.0% 27.0%
Other Income + 8 14 20 24 21 88 24 112 74 85 85 67 195
Interest 6 5 1 0 1 12 8 10 6 7 21 16 13
Depreciation 52 44 61 60 72 96 116 125 131 135 144 173 181
Profit before tax 456 559 648 623 514 664 900 909 745 1,114 1,189 1,378 1,688
Tax % 32.0% 26.0% 22.0% 25.0% 25.0% 30.0% 27.0% 22.0% 21.0% 27.0% 23.0% 23.0% —
Net Profit + 310 416 507 469 387 468 654 713 588 816 920 1,056 1,263
EPS in Rs 23 31 38 36 30 36 50 56 46 64 74 85 101
Dividend Payout % 17.0% 17.0% 23.0% 0.0% 20.0% 24.0% 13.0% 11.0% 15.0% 79.0% 38.0% 33.0% —
Sales growth 22 19 13 7 -3 26 12 16 12 12 10 17 25

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 823 1,173 1,550 2,024 2,228 2,581 2,978 3,247 3,363 3,542 3,765 4,502 4,833
Borrowings + 72 81 1 2 36 75 31 25 36 35 47 260 154
Other Liabilities + 233 207 254 383 383 619 702 711 1,159 927 1,067 1,250 1,413
Total Liabilities 1,146 1,479 1,823 2,426 2,664 3,293 3,729 4,000 4,582 4,530 4,904 6,037 6,425
Fixed Assets + 288 451 589 1,053 1,178 1,472 1,541 1,512 1,496 1,479 1,762 1,867 1,926
CWIP 170 240 339 61 262 132 108 153 209 256 176 258 327
Investments 60 86 182 190 78 79 176 147 535 349 464 588 620
Other Assets + 629 703 713 1,122 1,147 1,610 1,904 2,188 2,341 2,446 2,502 3,324 3,552
Total Assets 1,146 1,479 1,823 2,426 2,664 3,293 3,729 4,000 4,582 4,530 4,904 6,037 6,425
Equity Capital 18 18 18 18 18 18 17 17 25 25 25 25 25

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 279 326 609 281 375 457 576 562 792 785 1,157 529
Cash from Investing Activity + -158 -209 -383 -256 -223 -224 -282 -74 -560 65 -377 -429
Cash from Financing Activity + -105 -117 -202 0 -147 -129 -318 -460 -108 -1,051 -733 -168
Net Cash Flow 16 0 24 25 4 104 -24 28 124 -201 47 -68
Free Cash Flow 176 29 313 19 32 228 417 431 618 646 840 169
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 84 82 110 64 87 89 81 86 117 94 117 59

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 66.22% → 63.47%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 8.0% 7.76% 7.94% 7.51% 7.45% 7.38% 7.38% 7.32% 7.2% 7.14% 7.03% 6.96%
Promoters 66.22% 66.22% 66.27% 66.26% 66.26% 66.26% 66.26% 66.25% 66.25% 66.25% 63.49% 63.47%
Government 0.0% 0.0% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.0% 0.0%
FII 9.11% 8.54% 8.36% 9.11% 9.26% 8.86% 8.86% 8.53% 7.97% 8.26% 7.68% 7.62%
DII 16.67% 17.48% 17.41% 17.09% 17.02% 17.48% 17.5% 17.9% 18.58% 18.36% 21.8% 21.94%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Ajanta Pharma Limited (this stock) 41,393 32.8 8.51 27.1%
Sai Life Sciences Limited 41,003 107.0 15.19 15.4%
Global Health Limited 38,864 60.0 8.97 15.2%
Emcure Pharmaceuticals L 44,370 39.9 8.29 20.1%
Narayana Hrudayalaya Ltd. 37,889 41.8 7.57 20.5%
Glaxosmithkline Pharma Lt 45,576 40.2 24.22 45.6%
Ipca Laboratories Ltd 46,508 32.3 5.36 15.7%

Which Mutual Funds Hold Ajanta Pharma Limited?

Frequently Asked Questions about Ajanta Pharma Limited

Community Sentiment

What are other investors saying about Ajanta Pharma Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.